---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-22-000021"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:49:38.099665+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q2 2022 revenue up 5% to $466.9M; net income down 33%

## Summary
- Total revenues $466.9M (+5% YoY); net income $116.0M ($2.41 diluted EPS) vs $172.6M ($3.65) in Q2 2021.
- Tyvaso sales $201.0M (+31%) from PH-ILD label expansion; ~500 additional Tyvaso patients in Q2.
- Share-based compensation $65.5M (+125%), driven by STAP expense from 31% stock price increase.
- FDA approved Tyvaso DPI in May 2022 for PAH and PH-ILD; commercial shipments began in June.
- CMS updated Tyvaso coverage for PH-ILD effective June 5, 2022, supporting further patient growth.

## SEC filing metadata
- accession: 0001082554-22-000021
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000021/0001082554-22-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000021/uthr-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-22-000021
- JSON: https://secwatch.observer/filing/0001082554-22-000021.json
- Plain text: https://secwatch.observer/filing/0001082554-22-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.